

DAFTAR PUSTAKA

- Ahn, K. J., Park, J., & Choi, Y. (2017). Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery. *Radiation Oncology Journal*, 35(4), 332–339.
- Anders, C. K., Carey, L. A., Klauber-DeMore, N., Perou, C. M., & Livasy, C. (2009). The Triple Negative Phenotype. In M. A. Pegram & H. W. L. (Eds.), *Triple Negative Breast Cancer* (pp. 5-15). Humana Press.
- Araki, K., Miyoshi, Y., (2018). Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. *Spinger Nature Link*, Vol 25, P 392-401, (2018).
- Bando, Y., Kobayashi, T., Miyakami, Y., Sumida, S., Kakimoto, T., Saijo, Y., Uehara, H., (2021). Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy. *The Journal of Medicine Investigation*. 2021 Vol 68, P 213-219.
- Baranova, A., Krasnoselskyi, M., Starikov, V., Kartashov, S., Zhulkevych, I., Vlasenko, V., Oleshko, K., Bilodid, O., Sadchikova, M., Vinnyk, Y., (2022). Triple-negative breast cancer: current treatment strategies and factors of negative prognosis. *J Med Life*. 2022 Feb;15(2):153–161.
- Bhargava, R., Striebel, J., Beriwal, S., Flickinger, J.C., Onisko, A., Ahrendt, G. dan Dabbs, D.J. (2009). Prevalence, Morphologic Features and Proliferation Indices of Breast Carcinoma Molecular Classes Using Immunohistochemical Surrogate Markers. *International Journal of Clinical and Experimental Pathology*, 2(5), hlm. 444–455
- Carey, K.A. and Carey, L.A. (2009) 'Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer', *Review of Clinical Breast Cancer*, 9(Suppl 2), pp. S73-S81. doi: 10.3816/CBC.2009.s.008
- Carey, L. A., Perou, C. M., Livasy, C. A., et al. (2006) 'Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study', *JAMA*, 295(21), pp. 2492-2502.
- Chen, H., Wu, J., Zhang, Z., Tang, Y., Li, X., Liu, S., Cao, S., Li, X. (2018). Association Between *BRCA* Status and Triple-Negative Breast Cancer: A Meta-Analysis. *Sec. Cancer Molecular Targets and Therapeutics*, Vol 9-2018.



UNIVERSITAS
GADJAH MADA

Hubungan Ekspresi mRNA Phosphatidyl-Inositol-3-Kinase (PI3K) dan Mammalian Target OF Rapamycin (mTOR) dengan Invasi Limfovaskular dan Metastasis Kelenjar Getah Bening Ipsilateral pada Triple Negative Breast Cancer Operable

Dian Ibnu Wahid, Dr. dr. Artanto Wahyono, Sp.B.Subsp.Onk(K); Prof. Dr. dr. Teguh Aryandono, Sp.B.Subsp.Onk(K);
Universitas Gadjah Mada, 2026 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Chen, Y., Zhou, X., (2020). Research progress of mTOR inhibitors. *European Journal of Medicinal Chemistry*, Vol 208, 2020.

Costa RLB, Han HS, Gradishar WJ. (2018) Targetting The PI3K/AKT/mTOR Pathway In Triple-Negative Breast Cancer: A Review. *Breast Cancer Research and Treatment*. 2018 Vol 6, p 397-406.

Courtney, D., Davey, M.G., Moloney, B.M., Barry, M.K., Sweeney, K., McLaughlin, R.P., Malone, C.M, Lowery, A.J., Kerin, M.J., (2022). Breast cancer recurrence: factors impacting occurrence and survival. *Irish Journal of Medical Science*, Volume 191, pages 2501–2510, (2022).

Cretella, D., Ravelli, A., Fumarola, C., Monica, S.L., Digiacomo, G., (2018). The antitumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. *Journal of Experimental & Clinical Cancer Research*. Vol 37, No 72, 2018.

Deng, S., Leong, H.C., Datta, A., Gopal, V., Kumar, A.P. dan Yap, C.T. (2022). PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression. *Cancers*, 14(7), hlm. 1652.

Dong, C., Wu, J., Chen, Y., Nie, J., Chen, C., (2021). Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. *Sec. Pharmacology of Anti-Cancer Drugs*, Volume 12 - 2021

Duronio, V., (2008). The life of a cell: apoptosis regulation by the PI3K/PKB pathway. *Biochem J* (2008) 415 (3): 333–344

Eastman, A., Tammaro, Y., Moldrem, A., Andrews, V., Huth, J., Euhus, D., Leitch, M. dan Rao, R. (2013). Outcomes of Delays in Time to Treatment in Triple Negative Breast Cancer. *Annals of Surgical Oncology*, 20, hlm. 1880–1885.

Falck, A.K., Ferno, A., Bendahl, P.O., Ryden, L. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial, *BMC Cancer* 13, Number:558 (2013).

Ferrari, P., Scatena, C., Ghilli, M., Bargagna, I., Lorenzini, G., Nicolini, A., (2022). Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. *Int. J. Mol. Sci.* 2022, 23(3), 1665



UNIVERSITAS
GADJAH MADA

Hubungan Ekspresi mRNA Phosphatidyl-Inositol-3-Kinase (PI3K) dan Mammalian Target OF Rapamycin (mTOR) dengan Invasi Limfovaskular dan Metastasis Kelenjar Getah Bening Ipsilateral pada Triple Negative Breast Cancer Operable

Dian Ibnu Wahid, Dr. dr. Artanto Wahyono, Sp.B.Subsp.Onk(K); Prof. Dr. dr. Teguh Aryandono, Sp.B.Subsp.Onk(K);

Universitas Gadjah Mada, 2026 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Fuentes, J.D.B., Morgan, E., Aguilar, A.D.L. (2023). Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis. *JAMA Oncol.* 2024;10(1):71-78

Gautama W. (2022) Breast Cancer in Indonesia in 2022: 30 Years of Marching in Place. *Indones J Cancer.* 2022 ;16(1):1

Gondhowiardjo, S., Hartanto, S., Wirawan, S., Jayalie, V.F., Astiti, I.A.P., Panigoro, S.S. dan et al. (2021). Treatment delay of cancer patients in Indonesia: a reflection from a national referral hospital. *Medical Journal of Indonesia*, 30(2), hlm. 129-137

Götz, Rudolf. (2008). Inter-cellular adhesion disruption and the RAS/RAF and β catenin signalling in lung cancer progression. *Cancer cell international*. 8. 7. 10.1186/1475-2867-8-7.

Grasset, E.M., Dunworth, M., Sharma, G., Loth, M., TAndurella, J., Mathews, A.C., (2022). Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin. *Science Translational Medicine* Vol 14, Issue 656. 2022.

Gujam, F. J., Going, J. J., Mohammed, Z. M., Orange, C., Edwards, J., & McMillan, D. C. (2014). Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. *BMC Cancer*, 14, 676.

Hare, S.H., Harvey, A.J., mTOR function and therapeutic targeting in breast cancer. *Am J Cancer Res*, 2017 Mar 1;7(3): 383-404.

Hong R, Xu B. Breast cancer: an up-to-date review and future perspectives. *Cancer Commun.* 2022;42(10):913–36.

Hoxhaj, G. dan Manning, B.D. (2020). The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. *Nature Reviews Cancer*, 20(2), hlm. 74–88.

Hu, H., Zhu, J., Zhong, Y., Geng, R., Ji, Y., Guan, Q., Hong, C., Wei, Y., Min, N., Qi, A., Zhang, Y., Li, X., (2021). PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway. *Ann Transl Med.* 2021 Mar;9(5):410.



UNIVERSITAS
GADJAH MADA

Hubungan Ekspresi mRNA Phosphatidyl-Inositol-3-Kinase (PI3K) dan Mammalian Target OF Rapamycin (mTOR) dengan Invasi Limfovaskular dan Metastasis Kelenjar Getah Bening Ipsilateral pada Triple Negative Breast Cancer Operable

Dian Ibnu Wahid, Dr. dr. Artanto Wahyono, Sp.B.Subsp.Onk(K); Prof. Dr. dr. Teguh Aryandono, Sp.B.Subsp.Onk(K);

Kamdje A.H.N., Etet, P.F.S., Vecchio, L., Muller, J.M., Krampera, M., Lukong, K.E.,
(2014). Signaling pathways in breast cancer: Therapeutic targeting of the
microenvironment. *Cellular Signalling*, Vol 26, Issue 12, P 2843-2856

Karar, J., Maity, A., (2011). PI3K/AKT/mTOR pathway in angiogenesis. *Front. Mol. Neurosci.* Vol 4, 2011.

Kashiwagi, S., Yashiro, T., Nomura, S., Noda, S., Kawajiri, H., Wakasa, K., Hirakawa, K., (2010). Significance of E-cadherin expression in triple-negative breast cancer. *British Journal of Cancer* 103, 249-255 (2010).

Khan A, Jain K, Rizwanullah, Ahmad, Jain. (2019) PI3K/AKT/mTOR pathway inhibitors in Triple Negative Breast Cancer: A Review On Drug Discovery and Future Challenges. *Drug Discov Today*. 2019;24(11):2181-2191

Kim, M.S., Kuehn, H.S., Metcalfe, D.D., Gilfillian, A.M., (2008). Activation and Function of the mTORC1 Pathway in Mast Cells. *J Immunology* (2008) 180 (7): 4586-4595

Kortholt, A., Bolourani, P., Rehmann, H., Gunnink, I.K, Weeks, G., Wittinghofer, A., Haastert, P.J.M.V. (2010). A Rap/Phosphatidylinositol 3-Kinase Pathway Controls Pseudopod Formation. *Molecular Biology of The Cell*, Vol 21, No 6.

Krishnamurti, U., Wetherilt, C. S., Yang, J., Peng, L., & Li, X. (2017). Tumorinfiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. *Human Pathology*, 64, 7–12.

Kulkarni, A., Kelkar, D. A., Parikh, N., Shashidhara, L. S., Koppiker, C. B., & Kulkarni, M. (2020). Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer. *JCO Global Oncology*, 6. <https://doi.org/10.1200/GO.20.00054>

Lapiente, M., Sabatini, D.M., (2011). mTOR Signaling. Cold Spring Harbor Laboratory, Published in Advance November 2011.

Lapiente, M., Sabatini, D.M., (2013). Regulation of mTORC1 and its impact on gene expression at a glance. *J Cell Sci* (2013) 126 (8): 1713–1719.

Lee, M., Yoo, T.K., Chae, B.J., Lee, A., Cha, Y.J., Lee, J., Ahn, S.G., Kang, J., (2024). Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups

- Li, C.J., Tzeng, Y.D.T., Chiu, Y.H., Lin, H.Y., Hou, M.F., Chu, P.Y., (2021). Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer. *Cancers* **2021**, *13*(12), 2978.
- Li, H., Lin, J., Wang, X., Yao, G., Wang, L., Zheng, H., Yang, C., Jia, C., Liu, A., Bai, X., (2012). Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Springer Nature Link, Vol 134, P 1057-1066.
- Liu, B., Xiong, J., Liu, G., Wu, J., Wen, L. Zhang, Q. and Zhang, C. (2017), “High expression of rac1 is correlated with partial reversed cell popularity and poor prognosis in invasive ductal carcinoma of the breast”, *Tumor Biology*, SAGE Publications Ltd, Vol. 39 No.7, pp. 1-8, doi: 10.1177/1010428317710908
- Lin, C. Y., Huang, H. P., Yu, H. Y., Chen, Y. L., Chen, K. H., & Yang, S. F. (2019). Clinical characteristics and prognosis of triple-negative breast cancer in Taiwan. *Journal of the Chinese Medical Association*, *82*(2), 114-119.
- Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. *Cancers*. 2021;*13*(17):4287.
- Ma, M., Ma, Y., Zhang, G.-J., Liao, R., Jiang, X.-F., Yan, X.-X., Bie, F.-J., Li, X.-B. dan Lv, Y.-H. (2017). Eugenol alleviated breast precancerous lesions through HER2/PI3K-AKT pathway-induced cell apoptosis and S-phase arrest. *Oncotarget*, *8*, hlm. 56296–56310.
- Maharati, A., Moghbeli, M., (2023). PI3K/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells. *Cell Communication and Signaling*. 21, Article number: 201 (2023).
- Makki, J. (2015). Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. *Clinical Medicine Insights: Pathology*, *8*, 23–32. <https://doi.org/10.4137/CPath.S31563>
- Mendez, M.E., Arias, P.L., Orozco, J.I., Munoz, S.I., Salomon, M.P., Sese, B., DiNome, M.L., Marzese, D.M., (2021) Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer. *Front Oncol*, 2021, Vol 11.
- Mezi, S., Botticelli, A., Pomati, G., Cerbelli, B., Scagnoli, S., Amirhassankhani, S., D’amati, G., Marchetti, P., (2021) Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer. *Cancers* 2021, *13*(5), 1080.

- Miller, T. W., & Gonzalez-Angulo, A. M. (2014). The PI3K/Akt/mTOR pathway in breast cancer progression and metastasis. *Clinical Cancer Research*, 20(12), 3052–3058
- Min, S.K., Lee, S.K., Woo, J., Jung, S.H., Ryu, J.M., Yu, J., Lee, J.E., Kim, S.W., Chae, B.J., Nam, S.J., (2021). Relation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer. *J Breast Cancer*, 2021 Jan 22;24(1):75–84
- Montero JC, Esparís-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, Ocaña A, Pandiella A. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. *Oncogene*. 2014 Jan 9;33(2):148-56
- Nishimura, R. Osako, T. Okumura, Y. Nakano, M. Otsuka, H. Fujisue, M. Arima, N. (2022), Triple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast Cancer. *J Clin Med*. 2022 Apr 22;11(9):2331.
- Noh, W.C., Kim, Y.H., Kim, M.S., Koh, J.S., Kim, H.A., Moon, N.M., Paik, N.S., (2008). Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. *Spinger Nature Link*, Vol 110, P 477-483.
- Pagoda, K., Niwinska, A., Murawska, M., Pienkowski, T., (2013). Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. *Spinger Nature Link*. Vol 30, No 388, (2013).
- Perou, C. M., Sørli, T., Eisen, M. B., et al. (2000) 'Molecular portraits of human breast tumours', *Nature*, 406(6797), pp. 747-752.
- Prat, A., Adamo, B., Cheang, M.C., Anders, C.K., Carey, L.A., Perou, C.M., (2013). Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer. *The Oncologist*, Vol 18, Issue 2, Feb 2013, P 123-133.
- Prvanović, M., Nedeljković, M., Tanić, N., et al. (2021) 'Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer', *International Journal of Molecular Sciences*, 22(12), pp. 6278.
- Rakha, E.A., Chan, S., (2011). Metastatic Triple-negative Breast Cancer. *Clinical Oncology*, Vol 23, Issue 9, No 11, P 587-600.



UNIVERSITAS
GADJAH MADA

Hubungan Ekspresi mRNA Phosphatidyl-Inositol-3-Kinase (PI3K) dan Mammalian Target OF Rapamycin (mTOR) dengan Invasi Limfovaskular dan Metastasis Kelenjar Getah Bening Ipsilateral pada Triple Negative Breast Cancer Operable

Dian Ibnu Wahid, Dr. dr. Artanto Wahyono, Sp.B.Subsp.Onk(K); Prof. Dr. dr. Teguh Aryandono, Sp.B.Subsp.Onk(K);

Universitas Gadjah Mada, 2026 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Rigon, E. Saggia, C. Rossi, V. Genestroni, S. Gaudino, E. Campisi, P. (2015), FISH in Triple-Negative Breast Cancer: A Possible Strategy for the Future?. *Future Oncology*, Vol 11, 2015 P 1023-1026

Rozhenchan, P.B., Pasini, F.S., Roela, R.A., Katayama, M.L.H., Mundim, F.G.L., Brentani, H., Lyra, E.C., et al. (2015), "Specific upregulation of RHOA and RAC1 in cancer-associated fibroblasts found at primary tumor and lymph node metastatic sites in breast cancer", *Tumor Biology*, Springer Science and Bussiness Media B.V., Vol.36 No.12, pp. 9589-9597, doi: 10.1007/s13277-0153727-1.

Ryu, D.W., Lee, C.H., (2012). Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death. *Journal of the Korean Surgical Society* 2012; 83(4): 187-195.

Sadeghi, N., Gerber, D., (2012). Targeting the PI3K pathway for cancer therapy. *Future Medicinal Chemistry*, 2012.

Sasaki, A.T., Janetopoulos, C., Lee, S., Charest, P.G., Takeda, K., Sundheimer, L.W., Meilli, R., Devreotes, P.N., Firtel, R.A., (2007). G protein-independent Ras/PI3K/F-actin circuit regulates basic cell motility. *J Cell Biol* (2007) 178 (2): 185–191.

Schoppmann, S. F., Bayer, G., Aumayr, K., Uhrin, P., Seidl, D., & Jakesz, R. (2004). Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. *Annals of Surgery*, 240(2), 306–312.

Scutt, D., Lancaster, G.A. dan Manning, J.T. (2006). Breast asymmetry and predisposition to breast cancer. *Breast Cancer Research*, 8(2), hlm. R14.

Sen, B., Xie, Z., Case, N., Thompson, W.R., Uzer, G., Styner, M., Rubin, J., (2013). mTORC2 Regulates Mechanically Induced Cytoskeletal Reorganization and Lineage Selection in Marrow-Derived Mesenchymal Stem Cells. *Journal of Bone and Mineral Research*, Volume 29, Issue 1, 1 January 2014

Sheen, M.R., Marotti, J.D., Allegranza, M.J. (2016), Constitutively Activated PI3K Accelerates Tumor Initiation And Modifies Histopathology of Breast Cancer, *Oncogenesis* 5, e267, 2016.

Solikhah S, Perwitasari DA, Rejeki DSS. Geographic Characteristics of Various Cancers in Yogyakarta Province, Indonesia: A Spatial Analysis at the Community Level. *Asian Pac J Cancer Prev APJCP*. 2022; 23(4):1231–8.

Sridharan, S., Basu, A., (2020) Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer. *Int J Mol Sci*. 2020 Feb 11;21(4):1199



UNIVERSITAS
GADJAH MADA

Hubungan Ekspresi mRNA Phosphatidyl-Inositol-3-Kinase (PI3K) dan Mammalian Target Of Rapamycin (mTOR) dengan Invasi Limfovaskular dan Metastasis Kelenjar Getah Bening Ipsilateral pada Triple Negative Breast Cancer Operable

Dian Ibnu Wahid, Dr. dr. Artanto Wahyono, Sp.B.Subsp.Onk(K); Prof. Dr. dr. Teguh Aryandono, Sp.B.Subsp.Onk(K);

Universitas Gadjah Mada, 2026 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Stephen, H.H., Harvey, A.J. (2017), mTOR Function And Therapeutic Targeting In Breast Cancer, American Journal Of Cancer Research. Am J Cancer Res. 2017 Mar 1;7(3):383-404

Su, Y.C., Lee, W.C., Wang, C.C., Chen, W.H., Chen, P.J., (2022). Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas. *Int. J. Mol. Sci.* 2022, 23(24), 15749

Tarantino, P., Antonarella, G., Ascione, L., Curigliano, G., (2021). Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. *Expert Opinion on Investigational Drugs*, Vol 31, 2022, Issue 6. P 499-513.

Toschi, L., Lee, E., & Stokoe, D. (2008). PI3K/Akt/mTOR signaling in tumor angiogenesis and metastasis: a review. *BMC Cancer*, 8, 91

Venkitaraman, R., (2014). Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. *Exp Review of Anticancer Therapy.*, Vol 10, 2010, Issue 2, P 199-207

Wang, D.Y., Jiang, Z., David, Y.B., Woodgett, J.R., Zacksenhaus, E., (2019). Molecular stratification within triple-negative breast cancer subtypes. *Nature Scientific Reports*, Vol 9 Art Numb 19107 (2019).

Wang, L.L., Hao, S., Zhang, S., Guo, L.J., Hu, C.Y., Zhang, G., Gao, B., Zhao. (2017). PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases. *Human Pathology*, Vol 61, 2017, P 49-57.

Wang, W., Wu, J., Zhang, P., Fei, X., Zong, Y., Chen, X., Huang, O., He, J.-R., Chen, W., Li, Y., Shen, K. dan Zhu, L. (2016). Prognostic and predictive value of Ki67 in triple-negative breast cancer. *Oncotarget*, 7(21), hlm. 31079–31087.

Wu, Y., Shum, H.C.E., Wu, K., Vadgama, J., (2023). From Interaction to Intervention: How Mesenchymal Stem Cells Affect and Target Triple-Negative Breast Cancer. *Biomedicine* 2023, 11(4), 1182

Yamaguchi, J., Moriuchi, H., Ueda, T., Kawashita, Y., Hazeyama, T., Tateishi, M., Aoki, S., Uchihashi, K., Nakamura, M., (2021). Active behavior of triplenegative breast cancer with adipose tissue invasion: a single center and retrospective review. *Spinger Nature Link*. Vol 21, No 434 (2021).

Yin, L., Duan, J.J, Bian, X.W., Yu, S.C., (2020). Triple-negative breast cancer molecular subtyping and treatment progress, *Spinger Nature Link*, Vol 22, Num 61, (2020).



UNIVERSITAS
GADJAH MADA

Hubungan Ekspresi mRNA Phosphatidyl-Inositol-3-Kinase (PI3K) dan Mammalian Target OF Rapamycin (mTOR) dengan Invasi Limfovaskular dan Metastasis Kelenjar Getah Bening Ipsilateral pada Triple Negative Breast Cancer Operable

Dian Ibnu Wahid, Dr. dr. Artanto Wahyono, Sp.B.Subsp.Onk(K); Prof. Dr. dr. Teguh Aryandono, Sp.B.Subsp.Onk(K);

Universitas Gadjah Mada, 2026 | Diunduh dari <http://etd.repository.ugm.ac.id/>

- You, D., Jung, S.P., Jeong, Y., Bae, S.Y., Lee, J.E., Kim, S., (2017). Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells. *BMP Rep.* 2017 Dec 31;50(12): 615-620.
- Yuan, N., Meng, M., Liu, C., Feng, L., Hou, L., Ning, Q., Xin, G., Pei, L., Gu, S., Li, X. dan Zhao, X. (2013). Clinical characteristics and prognostic analysis of triplenegative breast cancer patients. *Molecular and Clinical Oncology*, 2(2), hlm. 245–251.
- Zhang HP, Jiang RYJ, Zhu JY, Sun KN, Huang Y, Zhou HH, Zheng YB, Wang XJ. (2024). PI3K/AKT/mTOR Signaling Pathway: An Important Driver and Therapeutic Target in Triple-Negative Breast Cancer. *Spinger Nature Link*. 2024. Vol 31, p 539-551.
- Zhang, Y., Li, J., Fan, Y., Li, X., Qiu, J., Zhu, M. and Li, H. (2019), “Risk factors for axillary lymph node metastases in clinical stage T1-2N0M0 breast cancer patients”, *Medicine (United States)*, Lippincott Williams and Wilkins, Vol. 98 No. 40, doi: 10.1097/MD00000000000017481
- Zheng, H., Siddharth, S., Parida, S., Wu, X., Sharma, D., (2021). Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation. *Cancers* 2021, 13(13), 3357
- Zheng, X., Xu, C., Ganesan, K., Chen, H., Cheung, Y.S. dan Chen, J. (2024). Does Laterality in Breast Cancer still have the Importance to be Studied? A Metaanalysis of Patients with Breast Cancer. *Current Medicinal Chemistry*, 31(22), hlm. 3360–3379.
- Zhou, H.L, Chen, D.D. (2023). Prognosis of Patients With Triple-negative Breast Cancer: A Population-based Study From SEER Database. *Clin Breast Cancer* Vol 23, Issue 3, Apr 2023, p e85-94
- Zhu, A., Li, Y., Xu, Y., Yang, F., Zhang, W., Yin, Y., Guan, X., (2016). Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal StemLike Triple-Negative Breast Cancer. *Cellular Physiology and Biochemistry* (2016) 38 (3): 1003–10